• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nanoviricides Inc (NY: NNVC )

    1.230 -0.110 (-8.21%)
    Official Closing Price Updated: 8:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Nanoviricides Inc

    < Previous 1 2 3 4 5 6 7 Next >
    NanoViricides Patents Its Antiviral Nanotechnology for COVID-19, Continuing Its Development of Potentially Broad-Spectrum Drugs That Are Expected To Be Effective Even Against Emerging Variants
    This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
    Via Benzinga
    58 Biggest Movers From Yesterday
    Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its complement portfolio for $60 million. 
    Via Benzinga
    NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis
    Via Benzinga
    30 Stocks Moving In Monday's Mid-Day Session
    Gainers Evolve Transition Infrastructure LP (NYSE: SNMP) shares rose 29.2% to $0.6699 after jumping around 14% on Friday. 
    Via Benzinga
    Mid-Morning Market Update: Markets Mixed; Broadcom In Talks To Buy VMWare
    U.S. stocks traded mixed this morning, with the Dow Jones gaining around 250 points on Monday. 
    Via Benzinga
    24 Stocks Moving in Monday's Pre-Market Session
    Gainers Genocea Biosciences, Inc. (NASDAQ: GNCA) shares rose 33.8% to $0.2795 in pre-market trading after declining around 5% on Friday. 
    Via Benzinga
    66 Biggest Movers From Friday
    Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year. 
    Via Benzinga
    The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
    Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
    Via Benzinga
    71 Biggest Movers From Yesterday
    Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation... 
    Via Benzinga
    CDC Looking Into 180 Cases Of Unexplained Pediatric Acute Hepatitis: CNBC
    The Centers for Disease Control and Prevention is now investigating 180 cases of children who suddenly developed severe hepatitis across 36 states and territories, an increase of 71 cases since the... 
    Via Benzinga
    NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application
    SHELTON, CT / ACCESSWIRE / May 17, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel... 
    From NanoViricides, Inc.
    Via AccessWire
    Topics Regulatory Compliance
    Exposures COVID-19 Legal Regulatory
    NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis
    SHELTON, CT / ACCESSWIRE / May 16, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel... 
    From NanoViricides, Inc.
    Via AccessWire
    Exposures COVID-19
    NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program
    SHELTON, CT / ACCESSWIRE / April 25, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel... 
    From NanoViricides, Inc.
    Via AccessWire
    Exposures COVID-19
    Pharmaceutical Companies Are Reportedly Refocusing On Mysterious Rise In Shingles Infections As COVID Declines
    Photo Credit: Photo by CDC & Klara Kulikova This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be... 
    Via Benzinga
    Does the FDA Rollback Of Regeneron And Eli Lilly COVID Treatment EUAs Signal A Need To Look Beyond Monoclonal Antibodies? NanoViricides, Inc. Looks To Meet This Need With A New Approach
    Photo credit: Marcelo Leal and Kate Hliznitsova on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended... 
    Via Benzinga
    27 Stocks Moving in Monday's Pre-Market Session
    Gainers Mullen Automotive, Inc. (NASDAQ: MULN) rose 45.4% to $1.00 in pre-market trading after the company reported progress on solid-state polymer battery pack development.... 
    Via Benzinga
    NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready
    SHELTON, CT / ACCESSWIRE / February 15, 2022 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel... 
    From NanoViricides, Inc.
    Via AccessWire
    Topics Regulatory Compliance
    Exposures COVID-19 Legal Regulatory
    How Many Boosters Will It Take? A Global Population Beset By Pandemic Fatigue Wants A More Permanent Solution
    Image provided by Pixabay This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
    Via Benzinga
    Booster Shots Might Not Be Enough to Beat Omicron, According to Some Nanotech Experts
    Image provided by Pixabay This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. As the threat... 
    Via Benzinga
    NanoViricides Attempts to Leverage Decades of Combined Pharmaceutical and Biotech Experience To Bring Broad-Spectrum COVID-19 Antiviral to Market
    Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
    Via Benzinga
    NanoViricides Says Its Nanomedicine Tech Could Be the Key To Defeating Omicron and Other COVID-19 Variants
    Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
    Via Benzinga
    Exposures COVID-19
    These Biotech Companies Are Attempting to Use Improved Antibody Technology in the Fight To Eradicate COVID-19
    Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
    Via Benzinga
    NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials
    SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel... 
    From NanoViricides, Inc.
    Via AccessWire
    Topics Regulatory Compliance
    Exposures COVID-19 Legal Product Safety
    EXCLUSIVE: NanoViricides Completes Oral Gummies, Lung Inhalation Formulations For COVID-19 Treatment
    NanoViricides, Inc. (NYSE: NNVC) announced Monday it has developed an oral gummies formulation of its COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized... 
    Via Benzinga
    Exposures COVID-19
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Welcome back, trader! We're getting right into the thick of it this week with a look at the biggest pre-market stock movers for Monday! 
    Via InvestorPlace
    NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2
    SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel... 
    From NanoViricides, Inc.
    Via AccessWire
    Exposures COVID-19 Product Safety
    EXCLUSIVE: NanoViricides Develops Chewable Pills, Lung Inhalation Formulations For COVID-19 Candidate
    NanoViricides Inc (NYSE: NNVC) has developed oral gummies formulations of its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. What... 
    Via Benzinga
    Exposures COVID-19
    Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
    Photo by Artem Podrez from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
    Via Benzinga
    Exposures COVID-19
    Are Pfizer, Moderna, J&J Booster Shots a Panacea? This Company Says Its Broad-Spectrum Drugs to Fight COVID-19 Would Help End the Pandemic
    Photo by Steven Cornfield on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
    Via Benzinga
    Exposures COVID-19
    NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage
    SHELTON, CT / ACCESSWIRE / October 13, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2021... 
    From NanoViricides, Inc.
    Via AccessWire
    Topics Intellectual Property Regulatory Compliance
    Exposures COVID-19 Intellectual Property Legal
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.